国泰海通证券股份有限公司 关于奥锐特药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 奥锐特药业股份有限公司（以下简称"奥锐特"或"公司"）向不特定对象发行 可转换公司债券及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》 《上海证券交易所股票上市规则》及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关法律法规及规范性文件的规定，对奥锐特首次公开 发行部分限售股上市流通的事项进行了核查，具体情况如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会出具的《关于核准奥锐特药业股份有限公司首次 公开发行股票的批复》（监许可[2020]1969 号文）核准，奥锐特药业股份有限公 司首次向社会公众公开发行人民币普通股（A 股）股票 41,000,000 股，并于 2020 年 9 月 21 日在上海证券交易所挂牌上市。公司首次公开发行后总股本 401,000,000 股，其中无限售条件流通股为 41,000,000 股，有限售条件流通股为 360,000,000 股。 本次上市流通的限售股为公司首次公开发 ...

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Group 1: Macro Economic Insights - The recent appreciation of the RMB against the USD may be seen as a "catch-up" due to a weaker dollar environment, with the RMB appreciating by approximately 2.3% compared to a 10% depreciation of the dollar index in the first eight months of 2025 [5][6][7] - The domestic equity market's recovery and dovish signals from the Federal Reserve are key triggers for the recent rise in the RMB exchange rate, despite weaker manufacturing PMI data [6][8] - The RMB is expected to continue appreciating, but short-term fluctuations may occur due to uncertainties in global economic policies, particularly in Japan [8][9] Group 2: ETF Market Dynamics - Since June, non-broad-based ETFs have seen rapid growth, with net inflows reaching 227.9 billion RMB, indicating a shift in retail investor preferences towards ETFs [11][12] - Broad-based ETFs have experienced significant net redemptions, suggesting that while overall ETF inflows may appear modest, retail funds are actively entering the market through non-broad-based ETFs [12][13] - The current bull market is characterized by a shift from actively managed funds to ETFs, driven by factors such as product variety, cost efficiency, and ease of access [13][14] Group 3: Power Equipment and New Energy Sector - The photovoltaic industry is facing severe overcapacity, with nominal production capacity exceeding 1200 GW, leading to significant price declines across the supply chain [18][19] - Recent government initiatives aim to curb internal competition and stabilize the market, with signs of price recovery in the polysilicon segment [19][20] - Despite ongoing losses in the main supply chain, specialized companies are performing better than integrated firms, indicating a potential for recovery as supply-demand dynamics improve [20][21] Group 4: Chemical Industry Performance - The chemical raw materials and products manufacturing sector reported a revenue of 4.46359 trillion RMB in H1 2025, a year-on-year increase of 1.4%, but profits fell by 9% to 181.46 billion RMB [23][24] - The basic chemical industry achieved a revenue of 1.1707 trillion RMB in H1 2025, with a profit of 73.17 billion RMB, reflecting a 3.5% revenue increase year-on-year [24][25] - The petrochemical sector, excluding major state-owned enterprises, saw a revenue decline of 7.3% in H1 2025, indicating challenges in profitability [25][26] Group 5: Pharmaceutical Sector Developments - Sunshine Nuohuo (688621.SH) reported a revenue of 590 million RMB in H1 2025, a 4.87% increase, with a significant Q2 performance showing a 15.73% year-on-year growth [28][29] - The company is advancing its innovative drug pipeline, with multiple projects in clinical trials, indicating a strong growth trajectory [29][30] - Haofan Bio (301393.SZ) achieved a revenue of 270 million RMB in H1 2025, reflecting a 20.10% increase, driven by strong demand for GLP-1 drugs [32][33] Group 6: Food and Beverage Sector Insights - Shanxi Fenjiu (600809.SH) reported a revenue of 23.96 billion RMB in H1 2025, a 5.4% increase, but faced pressure on profit margins due to changing consumer preferences [40][41] - Wuliangye (000858.SZ) achieved a revenue of 52.77 billion RMB in H1 2025, a 4.2% increase, but is navigating challenges in maintaining price stability amid competitive pressures [45][46]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 822 million yuan in the first half of 2025, representing a year-on-year increase of 12.50%. The net profit attributable to the parent company was 235 million yuan, up 24.55% year-on-year. The gross margin was 60.11%, an increase of 5.42 percentage points, while the net margin was 28.58%, up 10.73 percentage points [5][6] - The company is expected to maintain its profit forecast, with projected net profits attributable to the parent company of 486 million yuan, 591 million yuan, and 683 million yuan for 2025, 2026, and 2027 respectively. The current stock price corresponds to a PE ratio of 19.2, 15.8, and 13.6 for the respective years [5][8] Financial Performance - In the first half of 2025, the revenue from the raw materials and intermediates segment was 699 million yuan, reflecting a year-on-year growth of 24.67%. The core product in the formulation segment, Dydrogesterone tablets, achieved sales revenue of 97 million yuan, with 1,754 new hospital listings [6] - The company’s R&D expenses increased by 9.72% to 72 million yuan in the first half of 2025. A joint laboratory for AI small nucleic acid drug discovery was established with East China Normal University, focusing on obesity, aging, and Alzheimer's disease [7] Financial Summary and Valuation Metrics - The company’s projected revenue for 2025 is 1,985 million yuan, with a year-on-year growth of 34.5%. The gross margin is expected to reach 62.3%, and the net margin is projected at 24.5% [8][10] - The estimated earnings per share (EPS) for 2025 is 1.20 yuan, with a PE ratio of 19.2. The projected return on equity (ROE) for 2025 is 18.0% [8][10]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in stock price within the next 6 to 12 months [3][22]. Core Views - The company has shown strong performance in its financial results, with a revenue of 822 million yuan in the first half of 2025, representing a year-on-year growth of 12.50%. The net profit attributable to shareholders reached 235 million yuan, up 24.55% year-on-year [5]. - The company is expected to continue benefiting from the growth of its peptide and small nucleic acid products, with a robust pipeline and ongoing capacity expansion projects [5]. - The financial forecasts for 2025-2027 indicate a revenue growth of 20.60%, 19.33%, and 19.25% respectively, with net profits expected to grow by 32.84%, 30.18%, and 28.95% [5]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 822 million yuan, with a net profit of 235 million yuan, reflecting a strong growth trajectory [5]. - The second quarter of 2025 saw a revenue of 420 million yuan, a 6.31% increase year-on-year, and a net profit of 115 million yuan, up 8.53% year-on-year [5]. Product Development - The company is actively expanding its product pipeline, with significant growth in peptide and small nucleic acid raw materials. The sales revenue for these products reached 510 million yuan in the first half of 2025, a 14.82% increase [5]. - The core product, Dydrogesterone tablets, has seen a sales revenue of 95.68 million yuan in the first half of 2025, with plans to penetrate the tertiary hospital market further [5]. Research and Development - The company has increased its R&D investment, with R&D expenses amounting to 71.8 million yuan in the first half of 2025, representing 8.74% of its revenue [5]. - The establishment of an AI small nucleic acid drug discovery laboratory in collaboration with East China Normal University is expected to open new growth avenues [5]. Profitability Metrics - The gross margin for the first half of 2025 was 60.11%, an increase of 3.09 percentage points year-on-year, while the net margin was 28.58%, up 2.77 percentage points [5]. - The company has maintained stable expense ratios, with sales and management expense ratios showing slight decreases [5].

格隆汇9月1日丨奥锐特(605116.SH)公布，截至2025年8月31日，公司通过上海证券交易所交易系统以集 中竞价交易方式已累计回购公司股份141.42万股，占公司目前总股本的比例为0.35%，回购成交的最高 价为21.30元/股，最低价为18.83元/股，支付的资金总额为人民币28,220,158.00 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-065 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 签署初始资金为人民币_7,632.35__万元 | | --- | --- | | 投资种类 | 协定存款 | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 奥锐特药业股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开第 三届董事会第十五次会议及第三届监事会第十二次会议分别审议通过了《关于使 用部分闲置募集资金进行现金管理的议案》，同意公司及子公司使用闲置募集资 金不超过人民币 1 亿元进行现金管理，上述额度可以滚动使用，自第三届董事会 第十五次会议审议通过之日起 12 个月内有效，并授权公司管理层在上述额度内 行使决策权，具体事项由公司财务部负责组织实施。 具体内容详见公司于 2025 年 8 月 ...

| 证券代码：605116 | 证券简称：奥锐特 | 公告编号：2025-064 | | --- | --- | --- | | 债券代码：111021 | 债券简称：奥锐转债 | | 扣除公司回购专户库存股为分配基数进行利润分配，每股派发现金红利 0.29 元现 金（含税），公司不送红股，不进行资本公积转增。根据《奥锐特药业股份有限公 司关于以集中竞价交易方式回购股份的回购报告书》：如公司在回购期限内公司实 施了资本公积金转增股本、派送股票或现金红利、股票拆细、缩股或配股等除权 除息事项，公司将按照中国证监会及上海证券交易所的相关规定，对回购股份的 价格进行相应调整。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 1 月 | 年 | 月 | 21 | 日~2026 | 年 | 1 | ...

中国经济网北京9月1日讯奥锐特（605116）(605116.SH)近日发布了股东减持股份计划公告。因部分合 伙人自身资金需求，自公告发布之日起15个交易日后的3个月内(窗口期不减持)，天台铂融投资合伙企 业(有限合伙)(以下简称"天台铂融")拟通过集中竞价、大宗交易方式减持公司股份不超过2,176,600股， 即不超过公司总股本的0.54%。公司实际控制人不参与本次减持。 截至公告发布日，公司的股份总数为406,195,234股，天台铂融及其一致行动人浙江桐本投资有限公司、 天台铂恩投资管理合伙企业(有限合伙)合计持有公司股份170,096,400股，占公司总股本的41.88%。其中 天台铂融持有公司股份9,907,200股，占公司总股本的2.44%，浙江桐本持有公司股份153,583,200股，占 公司总股本的37.81%，天台铂恩持有公司股份6,606,000股，占公司总股本的1.63%。上述股份均来源于 公司首次公开发行股票前取得的股份。 奥锐特发布的《关于公司2024年度募集资金存放与实际使用情况的专项报告》显示，根据中国证券监督 管理委员会《关于同意奥锐特药业股份有限公司向不特定对象发行可转换公司 ...

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a robust business trajectory and potential for future expansion [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 822 million yuan, representing a year-on-year increase of 12.50% [1][2]. - The net profit attributable to shareholders was 235 million yuan, up 24.55% year-on-year, while the net profit excluding non-recurring items reached 226 million yuan, reflecting a growth of 20.94% [1][2]. - The gross margin and net margin for H1 2025 were 60.11% and 28.58%, respectively, showing improvements of 309 basis points and 277 basis points compared to the previous year [2]. Business Segments - The raw material pharmaceutical business exhibited rapid growth, with revenue in H1 2025 reaching 700 million yuan, a year-on-year increase of 24.68% [3]. - Key product categories such as cardiovascular, respiratory, women's health, nervous system, and anti-infection raw materials showed steady growth, while new products in the peptide and oligonucleotide segments contributed to sales growth [3]. Future Outlook - The company anticipates continued growth in key products like Dydrogesterone, Abiraterone, and others, alongside new product launches expected to drive revenue increases over the next 3-5 years [2][4]. - The company is focusing on expanding hospital coverage for Dydrogesterone, with 1,754 new hospital additions in H1 2025, leading to a sales revenue of approximately 95.7 million yuan, a 3.5% increase year-on-year [2]. Investment Recommendations - The company is expected to maintain high growth rates in the coming years due to the ongoing expansion of existing products and the commercialization of potential blockbuster products [4]. - Revenue forecasts for 2025-2027 have been adjusted to 1.777 billion, 2.154 billion, and 2.591 billion yuan, respectively, with corresponding EPS estimates revised to 1.15, 1.47, and 1.84 yuan [4].